U.S. Dollar Reaches One-Year High as Tech Sell-Off and Fed Rate Hike Expectations Support Demand 
South Korea’s KOSPI Rebounds as Samsung and SK Hynix Lead Tech Stock Recovery 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Trump Requests $11 Billion More in Farm Aid as Rising Costs Pressure U.S. Farmers 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Wall Street Ends Mixed as Tech Stocks Struggle Ahead of Micron Earnings 
Oil Prices Drop as Strait of Hormuz Shipping Recovers 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Japan Signals Preference for Low Interest Rates as BOJ Policy Debate Intensifies 
Australia Inflation Cools in May, But Core CPI Keeps RBA Rate Hike Risks Alive 
Wall Street Slides as AI Stocks Tumble Following South Korea Tech Sell-Off 
Australia Jobs Growth Strengthens Rate Hike Outlook 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Oil Prices Slip as Iran Sanctions Relief and Hormuz Shipping Recovery Ease Supply Concerns 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Asian Stocks Slip as Oil Rebounds Amid Fed Rate Hike Fears 
CJ Cheiljedang, South Korea’s largest food and beverage conglomerate, is set to buy Batavia Biosciences, a Dutch bio firm for $226 million or about €195 million. It was reported that the deal came not long after the company revealed its $8.5 billion growth plan for its four major business areas.
CJ Cheiljedang which is a subsidiary of CJ Group announced on Monday, Nov. 8, that it will be acquiring the said Dutch biotech company as part of its plan to broaden its presence in the contract biopharmaceutical production market.
According to The Korea Economic Daily, the company’s board of directors already gave the “go” signal for the acquisition of 75.8% share in Batavia Biosciences. It was reportedly posted in the regulatory filing that this deal is worth ₩267.7 billion or $226 million.
Moreover, CJ Cheiljedang shared it will buy 50,807 shares in the Leiden, Netherlands-headquartered biotech firm and this includes 13,007 new shares at €3,844 per share. It should be noted that the companies’ acquisition deal is still subject to approval by regulatory authorities in South Korea and the Netherlands.
Once the transactions are complete, CJ will immediately work on the expansion of its “red bio” business which refers to the line of work in the medical and pharmaceutical fields. “There’s no dominant leader in the gene therapy treatment market,” an official at CJ said in a statement. “We want to grow big in this area as soon as possible.”
Batavia Biosciences is based in the Netherlands but is has research and development (R&D) centers and sales offices in Hong Kong and Boston, U.S.A. It was founded by the researchers of Janssen Pharmaceuticals in 2010 and mainly worked on cell and gene therapies under CDMO or Contract Development and Manufacturing Organization program. It has extensive experience in virus vaccine, viral vector, monoclonal antibody, microbial vaccine, and recombinant protein development.
Finally, BioPharma reported that with its acquisition of Batavia Biosciences, it appears that CJ Group is directing its attention back to its pharmaceutical business. After unloading its healthcare unit to Kolmar Korea in 2018, CJ seems to have revived its interest in expanding in the biopharma line.
